Emerging strategies for cancer immunoprevention
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The crucial role of the immune system in the formation and progression of tumors has been widely accepted. On one hand, the surveillance role of the immune system plays an important role in endogenous tumor prevention, but on the other hand, in some special circumstances such as in chronic inflammation, the immune system can actually contribute to the formation and progression of tumors. In recent years, there has been an explosion of novel targeted immunotherapies for advanced cancers. In the present manuscript, we explore known and potential various types of cancer prevention strategies and focus on nonvaccine-based cancer preventive strategies targeting the immune system at the early stages of tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“Interleukin-6: The complex of IL-6 and IL-6R does not lead to signaling but instead associates with the protein gp130 inducing its dimerization and starting intracellular signaling via the JAK/STAT and the Ras-Raf-MAPK signaling pathways [32].”
BackgroundIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883 · cited 1×
“The vaccine against the hepatitis B virus (HBV) initially developed for hepatitis prevention has also been shown to reduce the incidence and mortality of liver carcinoma [13, 14].”
BackgroundIL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842 · cited 1×
“T H 17 and Interleukin-17: IL-17A, a pro-inflammatory cytokine produced mainly by CD4+T cells known as T H 17 (T Helper 17) cells, plays a key role in chronic inflammation-related human diseases and autoimmunity [56, 57].”
BackgroundWu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Self-citationMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491 · cited 1×
“Studies have also shown that anti-CD25 antibodies induce tumor rejection in mice [147, 148] and humans.”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 1×
“T H 17 and Interleukin-17: IL-17A, a pro-inflammatory cytokine produced mainly by CD4+T cells known as T H 17 (T Helper 17) cells, plays a key role in chronic inflammation-related human diseases and autoimmunity [56, 57].”
BackgroundHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · cited 1×
“High expression of tumoral PD-L1 has been associated with poor prognosis in multiple studies [109, 114].”
BackgroundThe Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Jego, G., Palucka, A. K., Blanck, J.-P., Chalouni, C., Pascual, V., & Banchereau, J. (2003) · Immunity · doi:10.1016/s1074-7613(03)00208-5 · Cited by 1,067 · cited 1×
“Finally, IFN-α can promote B cell differentiation, antibodies production and Ig class switching [169].”
BackgroundAkira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019 · cited 1×
“STAT3 was found to mediate the acute phase response observed with inflammation and stress that is often mediated by interleukin-6 (IL-6) and other proinflammatory cytokines [90].”
BackgroundEnhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 1×
“Tyrosine kinase oncoproteins can target constitutive STAT3 phosphorylation [95], and the ablation of STAT3 results in impairment of malignant transformation by tyrosine kinase oncoproteins [96–98].”
BackgroundInterferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1496401 · Cited by 899 · cited 1×
“…agents but further studies are needed [82] STAT3: STATs (signal transducers and activators of transcription) are a family of transcription factors discovered in the early 1990’s that regulate cell growth and differentiation through phosphorylation by receptor-associated kinases [89].”
BackgroundNomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex
Toy, D., Kugler, D., Wolfson, M., Bos, T. V., Gurgel, J., Derry, J., Tocker, J., & Peschon, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.36 · Cited by 570 · cited 1×
“IL-17A binds the heteromeric IL-17R complex consisting of at IL17RA and IL17RC [61].”
BackgroundInnate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529 · cited 1×
“In a murine model of bacteria induced-colon cancer, innate lymphoid cells have been shown to sustain tumorigenesis through production of interleukin-22 [129].”
BackgroundIwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
T-bet: a bridge between innate and adaptive immunity
Lazarevic, V., Glimcher, L. H., & Lord, G. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3536 · Cited by 486 · cited 1×
“CD4+T cells (TH1)— TH1 CD4+T cells are driven by IL-12 activation of Stat4 and T-bet transcription factors on naïve T cells [175, 176] that induces and up-regulates IFN γ [177].”
BackgroundMcAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · cited 1×
“Correspondence: Dr F McAllister, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1360, Houston, TX 77030, USA. E-mail: fmcallister@mdanderson.org Received 8 December 2015; revised 25 February 2015; accepted 27 February 2015; published online 14 September…”
BackgroundSelf-citationMyeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313 · cited 1×
“Finally, a chemically modified double-stranded STAT3 oligonucleotide decoy that inhibited tumorigenesis in murine models has also been clinically tested in a phase 0 setting and proved to be safe and effective to selectively suppress STAT3 target genes in head and neck tumors [103].”
BackgroundNowell, M. A., Williams, A. S., Carty, S. A., Scheller, J., Hayes, A. J., Jones, G. W., Richards, P. J., Slinn, S., Ernst, M., Jenkins, B. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.613 · Cited by 215 · cited 2×
“Using mice in which the portions of gp130 have been genetically modified in models of inflammatory diseases led to the conclusion that the IL-6-gp130-STAT3 axis was fundamentally required for the orchestration of the inflammatory process [34].”
BackgroundSchlessinger, K., & Levy, D. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0317 · Cited by 112 · cited 1×
“Tyrosine kinase oncoproteins can target constitutive STAT3 phosphorylation [95], and the ablation of STAT3 results in impairment of malignant transformation by tyrosine kinase oncoproteins [96–98].”
Background
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Highlighted STAT3 as a potential drug target for cancer therapy
Lee, H., Jeong, A. J., & Ye, S.-K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.152 · Cited by 295
Targeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
Metadata
- Authors
- Roeser, J. C., Leach, S. D., & McAllister, F.
- Venue
- Oncogene
- Published
- 2015-09-14
- Volume
- 34
- Issue
- 50
- Pages
- 6029-6039
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2200775887
- Cited by
- 52
- References
- 32
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.